Efficacy and Safety of a Fixed-Dose Combination of Candesartan and Rosuvastatin on Blood Pressure and Cholesterol in Patients With Hypertension and Hypercholesterolemia: A Multicenter, Randomized, Double-Blind, Parallel Phase III Clinical Study
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q2Scopus Q1
- 저널
- CLINICAL THERAPEUTICS41(8) · pp.1508 · 2019
- 피인용
- Web of Science 10Scopus 10
- FWCI (Scopus)
- 0.41
- JCR IF
- JCR 2018 2.935
- ISSN
- 0149-2918
저자
- Cho, Kyoung Im제1저자Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea
- 김보현교신저자Department of Internal Medicine, Pusan National University Hospital and Biomedical Research Institute, Busan, South Korea
- 박용현Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, South Korea
- Ahn, Jeong-CheonDepartment of Internal Medicine, Korea University Ansan Hospital, Seoul, South Korea
- Kim, Sang HyunDepartment of Internal Medicine, Seoul Boramae Hospital, Seoul National University College of Medicine, Seoul, South Korea
- Chung, Wook JinDepartment of Internal Medicine, Korea University Guro Hospital, Seoul, South Korea
- Kim, WeonDepartment of Internal Medicine, Gachon University Gil Medical Center, Incheon, South Korea
- Sohn, Il SukDepartment of Internal Medicine, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong, Seoul, South Korea
- Shin, Jin HoDepartment of Internal Medicine, Hanyang University College of Medicine, Seoul, South Korea
- Kim, Yong JinDepartment of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
- Chang, KiyukDepartment of Internal Medicine, The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, South Korea
- Yu, Cheol WoongDepartment of Internal Medicine, Korea University Anam Hospital, Seoul, South Korea
- Ahn, Soe HeeDepartment of Internal Medicine, Ulsan University Hospital, Ulsan, South Korea
- Kim, Seok YeonDepartment of Internal Medicine, Seoul Medical Center, Seoul, South Korea
- Ryu, Jae KeanDepartment of Internal Medicine, Daegu Catholic University Hospital, Daegu, South Korea
- Lee, Jong YoungDepartment of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea
- Hong, Bum KeeDepartment of Internal Medicine, Gangnam Severance Hospital, Seoul, South Korea
- Hong, Taek JongDepartment of Internal Medicine, Kosin University College of Medicine, Busan, South Korea
- Gyu Park, ChangDepartment of Internal Medicine, Korea University Guro Hospital, Seoul, South Korea
초록
Purpose: The aim of this study was to evaluate the blood pressure-lowering and cholesterol-lowering effects of a fixed-dose combination therapy using candesartan (CND)/rosuvastatin (RSV) compared with CND or RSV monotherapy in patients with hypertension and hypercholesterolemia. Methods: This study was a 12-week, randomized, double-blind, placebo-controlled, multicenter study. A total of 394 patients were screened. After a 4-week run-in period, 219 of these patients with hypertension and primary hypercholesterolemia were randomized. Patients received 1 of 3 regimens for 8 weeks: (1) CND 32 mg/RSV 20 mg, (2) RSV 20 mg, or (3) CND 32 mg. The primary outcome variables were changes in the systolic blood pressure (SBP) and diastolic blood pressure (DBP) and the percentage changes in LDL-C from baseline to the drug treatment at 8 weeks. The secondary outcome variables were percentage changes of total cholesterol, triglycerides, HDL-C, non-HDL-C, apolipoprotein B, apolipoprotein A-I, high-sensitivity C-reactive protein, and glucose metabolic indices, including percentage changes of the homeostasis model assessment of insulin resistance (HOMA-IR), adiponectin, and hemoglobin Air. Tolerability of combination therapy was compared with other monotherapy groups. Findings: The percentage changes of LDL-C were-48.6% (from 157.2 to 80.1 mg/dL) in the RSV group and -49.8% (from 160.2 to 78.9 mg/dL) in the CND/RSV group from baseline to the end of 8 weeks of treatment. Mean SBP and DBP were significantly decreased in the CND/RSV and CND groups after 8 weeks (P < 0.001 for all); however, no significant differences were found between the 2 groups. Total cholesterol levels, triglycerides, non-HDL-C, and apolipoprotein B were significantly reduced in the CND/RSV and RSV groups, with no significant differences between the groups compared with the CND group (P < 0.001 for all). The percentage changes of HOMA-IR, adiponectin, and hemoglobin A(1c) had no significant differences between the combination groups and monotherapy groups. However, in a 2-sample t test, HOMA-IR was significantly decreased in the CND/RSV group compared with the RSV group in nondiabetic patients (mean [SD] percentage change of HOMA-IR,-8.7% [37.6%] vs 17.1% [53.1%]; P = 0.048). There were no significant differences in metabolic indices between the diabetic groups. Adverse events in the CND/RSV group were similar to those in the monotherapy group. (C) 2019 Elsevier Inc. All rights reserved.
키워드
candesartandrug combinationdyslipidemiahypertensionrosuvastatin calciumANGIOTENSIN RECEPTOR BLOCKERSC-REACTIVE PROTEINPPAR-GAMMAPRIMARY PREVENTIONRISKSTATINSHYPERLIPIDEMIAMETAANALYSISTELMISARTANASSOCIATION
식별자
- Scopus EID
- 2-s2.0-85068767709
- WoS UID
- 000487768700012



로그인
연구물 목록으로